▲ Up
 
21:17 16-08-2017
АКИpress CA-News Tazabek Turmush
ADVERTISE WITH US SUBSCRIBE
KazakhstanKyrgyzstanMongoliaTajikistanTurkmenistanUzbekistanWorld
POLITICSBUSINESSINCIDENTSSOCIETYCULTURESPORTANALYSISSCIENCE
India's Sun Pharma buys Ranbaxy for $4 billion
15:31, 07 April 2014, 752

AKIPRESS.COM - Sun_Pharma India's Sun Pharmaceutical Industries is buying troubled generic drugmaker Ranbaxy Laboratories in a $4 billion all-stock transaction, Miami Herald reported today.

The combined company will be India's biggest pharmaceutical firm, with annual revenue estimated at $4.2 billion.

Shares of Sun Pharma rose 1.7 percent. Ranbaxy's shares were down 4.8 percent in trading on the Bombay Stock Exchange.

Ranbaxy is the leading drugmaker in India's $26 billion generic pharmaceutical industry, but it has faced penalties from U.S. regulators for years. The U.S. has banned imports of drugs from two of its factories because of concerns about quality control.

The acquisition will allow Sun Pharma to tap into Ranbaxy's strong global presence and manufacturing capabilities. The combined company will have 47 factories across five continents and operations in 65 countries.

Ranbaxy has annual revenue of about $2 billion.


Full access to all news articles in English

1 month2000 somsubscribe
year20000 somsubscribe
These subscription fees are for private individuals only. Please contact us via phone +996 (312) 900-776 or email info@akipress.org for corporate subscription inquiries
Twitterfacebookprint
© AKIpress News Agency - 2001-2017. All rights reserved
Republication of any material is prohibited without a written agreement with AKIpress News Agency. Any citation must be accompanied by a hyperlink to akipress.com.
Our address:
Moskovskaya str. 189, Bishkek, the Kyrgyz Republic
e-mail: english@akipress.org, akipressenglish@gmail.com;
Tel/Fax: +996(312)90-07-75